Open Access Open Badges Research article

Effects of esomeprazole treatment for gastroesophageal reflux disease on quality of life in 12- to 17-year-old adolescents: an international health outcomes study

Thirumazhisai Gunasekaran12*, Vasundhara Tolia37, Richard B Colletti4, Benjamin D Gold5, Barry Traxler6, Marta Illueca6 and Joseph A Crawley6

Author Affiliations

1 Lutheran General Children's Hospital, 1675 Dempster Street, Park Ridge, IL 60068, USA

2 Loyola Medical Center, 2160 South 1st Street, Maywood, IL 60153, USA

3 Wayne State University, 4743 Cass Avenue, Detroit, MI 48201, USA

4 University of Vermont, 201 South Prospect Street, Burlington, VT 05401, USA

5 Emory University School of Medicine, 1648 Pierce Drive, Atlanta, GA 30322, USA

6 AstraZeneca LP, 1800 Concord Pike, Wilmington, DE 19803, USA

7 Providence Hospital, Southfield, MI, USA

For all author emails, please log on.

BMC Gastroenterology 2009, 9:84  doi:10.1186/1471-230X-9-84

Published: 18 November 2009



Although gastroesophageal reflux disease (GERD) is common in adolescents, the burden of GERD on health-related quality of life (HRQOL) in adolescents has not been previously evaluated. Therefore, the objective of the study was to examine the effect of GERD on HRQOL in adolescents.


This international, 31-site, 8-week safety study randomized adolescents, aged 12 to 17 years inclusive, with GERD to receive esomeprazole 20 or 40 mg once daily. The Quality of Life in Reflux and Dyspepsia questionnaire (QOLRAD), previously validated in adults, consists of 25 questions grouped into 5 domains: emotional distress, sleep disturbance, food/drink problems, physical/social functioning, and vitality. The QOLRAD was administered at the baseline and week-8 (final) visits.


Of the 149 patients randomized, 134 completed the QOLRAD at baseline and final visits and were eligible for analysis of their HRQOL data. Baseline QOLRAD scores indicated GERD had a negative effect on the HRQOL of these adolescents, especially in the domains of vitality and emotional distress, and problems with food/drink. At the final visit, mean scores for all 5 QOLRAD domains improved significantly (P < .0001); change of scores (ie, delta) for all domains met or exceeded the adult QOLRAD minimal clinically significant difference standard of 0.5 units.


GERD had a negative effect on QOL in adolescents. After esomeprazole treatment, statistically and clinically significant improvements occurred in all domains of the QOLRAD for these adolescents.

Trial Registration

D9614C00098; Identifier NCT00241501